Today we’re publishing an open letter to Government signed by us and 18 cancer charities, calling on them to prioritise the interests of people affected by cancer in the second phase of Brexit negotiations.
We’ve joined forces with 18 other cancer charities, including Cancer Research UK, Macmillan Cancer Support and The Brain Tumour Charity, to publish an open letter to the Government. We’re asking them to prioritise seeking continued alignment with the EU drug licensing process and ensuring the UK retains prompt access to the most innovative cancer treatments.
The European Medicines Agency (EMA) centralises drug licensing across the EU and is currently working on ways to better coordinate pan-EU clinical trials.
We want the Government to prioritise reaching an agreement which ensures regulatory alignment with the EU on clinical trials and drug licensing to ensure patient safety, timely access to medicines and our continued participation in clinical trials.
The Government has committed to maintaining close links with the EMA and we urge them to make this a priority in negotiations. They must send a clear message to patients that there will be no delays in access to the most innovative and effective cancer treatments after we leave the European Union.
Download our open letter to the Government to read it in full.